ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFIC

ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFICPRESS RELEASE Stockholm, August 18, 2004ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFICElekta will begin including state-of-the-art ultrasound targeting technology with its linear accelerator platforms, based upon a new worldwide distribution agreement between Elekta and North American Scientific, Inc.The inclusion of the BAT® SXi image-guided ultrasound technology with Elekta's highly precise digital linear accelerators for radiation therapy will provide clinicians with the ability to more aggressively treat cancer while avoiding damage to surrounding healthy tissue.BAT is an image-guided targeting system that provides fast ultrasound localization of a treatment target on a daily basis. Currently, it is most commonly used for treating prostate cancer. Combining ultrasound with a 3D tracking system and a touchscreen-based treatment room interface, BAT non-invasively pinpoints tumor targets rapidly and accurately at the time of a radiation therapy treatment. For further information, please contact:International: Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ),Phone: +46 733 611 000, e-mail: peter.ejemyr@elekta.com United States: Lars Jonsteg, VP Investor Relations North America, Elekta, USAPhone: +46 708 78 37 35, e-mail: lars.jonsteg@elekta.comElekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.For additional information about Elekta, please visit www.elekta.comAbout North American Scientific:North American Scientific is a leader in products for radiation therapy and patient assessment. Its innovative radioisotope-based products include brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera®. The Company is also a leading supplier of planning and delivery technology for intensity modulated radiation therapy (IMRT). Please visit www.nasmedical.com for more information.------------------------------------------------------------This information was brought to you by Waymaker http://www.waymaker.netThe following files are available for download:http://www.waymaker.net/bitonline/2004/08/18/20040818BIT21250/wkr0001.pdf PDF Version